{"id":5935,"date":"2023-06-08T16:02:56","date_gmt":"2023-06-08T20:02:56","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2023-06-21T10:26:45","modified_gmt":"2023-06-21T14:26:45","slug":"bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/","title":{"rendered":"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE)<\/strong>\u00a0\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago, Illinois on June 15 \u2013 18, 2023.<\/p>\n<p>At ENDO 2023, BridgeBio will also present additional data from its achondroplasia program and nonclinical results from studies in hypochondroplasia. Furthermore, the Company will share updates from its autosomal dominant hypocalcemia type 1 (ADH1) program, including 18 month data from its ongoing Phase 2 study of encaleret in ADH1 and its sponsored hypoparathyroidism genetic testing program.<\/p>\n<p>To access the oral presentation and poster materials following the Company\u2019s participation at ENDO 2023, please visit\u00a0<a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/presentations\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/investor.bridgebiodev.wpengine.com\/presentations<\/a>.<\/p>\n<p><strong><u>Achondroplasia oral presentation and poster details:<\/u><\/strong><\/p>\n<p><strong>Oral infigratinib treatment is well tolerated and significantly increases height velocity in children with achondroplasia: Month 6 results from the PROPEL 2 dose-finding study<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Ravi Savarirayan, M.D., Ph.D., clinical geneticist and group leader of molecular therapies research at the Murdoch Children\u2019s Research Institute in Australia, the lead investigator for PROPEL2<br \/>\n<strong>Oral presentation date &amp; time:\u00a0<\/strong>Saturday, June 17 at 4:00 pm CT<br \/>\n<strong>Location:\u00a0<\/strong>W-184BC, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>Late Breaking II<br \/>\n<strong>Session number:\u00a0<\/strong>OR27-03<\/p>\n<p><strong>Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in murine models of achondroplasia and hypochondroplasia<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Elena Muslimova, Ph.D., medical director of skeletal dysplasias program at BridgeBio<br \/>\n<strong>Oral presentation date &amp; time:\u00a0<\/strong>Saturday, June 17 at 4:30 pm CT<br \/>\n<strong>Location:\u00a0<\/strong>W-178B, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>Update on pediatric growth disorders<br \/>\n<strong>Session number:\u00a0<\/strong>OR21-05<\/p>\n<p><strong>PROPEL, PROPEL 2 and PROPEL OLE studies of infigratinib in children with achondroplasia: design and status of 3 ongoing trials<br \/>\n<\/strong><strong>Poster presentation date &amp; time:\u00a0<\/strong>Thursday, June 15 at 12:30 pm CT<br \/>\n<strong>Location:<\/strong>\u00a0Board no. THU-165, ENDOExpo Hall, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>Pediatric endocrinology: Pediatric disorders of growth<br \/>\n<strong>Session number:\u00a0<\/strong>P10<\/p>\n<p><strong>Evaluation of bone mineral density in a cohort of children with achondroplasia participating in the PROPEL 2 study of infigratinib<\/strong><br \/>\n<strong>Poster presentation date &amp; time:\u00a0<\/strong>Thursday, June 15 at 12:30 pm CT<br \/>\n<strong>Location:\u00a0<\/strong>Board no. THU-181, ENDOExpo Hall, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>Pediatric endocrinology: Pediatric disorders of growth<br \/>\n<strong>Session number:\u00a0<\/strong>P10<\/p>\n<p><strong><u>ADH1 oral presentation, rapid fire presentation and poster details:<\/u><\/strong><\/p>\n<p><strong>Sustained normalization of mineral homeostasis in autosomal dominant hypocalcemia type 1: Results from a Phase 2 study over 18 months of encaleret (CLTX-305) treatment (NCT04581629)<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Rachel Gafni, M.D., senior research physician and head of the Mineral Homeostasis Studies Group of the National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH)<br \/>\n<strong>Oral presentation date &amp; time:\u00a0<\/strong>Saturday, June 17 at 4:00 pm CT<br \/>\n<strong>Location:\u00a0<\/strong>W-183C, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>PTH \u2013 Relevant biology, pathophysiology, and therapeutics<br \/>\n<strong>Session number:\u00a0<\/strong>OR23-03<\/p>\n<p><strong>Next-generation sequencing for detection of underlying genetic causes of nonsurgical hypoparathyroidism: Preliminary results from a sponsored testing program<\/strong><br \/>\n<strong>Presenter:\u00a0<\/strong>Michael Mannstadt, M.D., chief of the Endocrine Unit at Massachusetts General Hospital and associate professor in Medicine at Harvard Medical School<br \/>\n<strong>Rapid fire presentation date &amp; time:\u00a0<\/strong>Saturday, June 17 at 1:00 pm CT<br \/>\n<strong>Poster presentation date &amp; time:\u00a0<\/strong>Saturday, June 17 at 1:00 pm CT<br \/>\n<strong>Location:<\/strong>\u00a0Board no. SAT-231, ENDOExpo Hall, McCormick Place<br \/>\n<strong>Session title:\u00a0<\/strong>Bone and mineral metabolism: hypoparathyroidism<br \/>\n<strong>Session number:\u00a0<\/strong>P69<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\nBridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit \u00a0<a href=\"https:\/\/www.bridgebio.local\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>bridgebiodev.wpengine.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/6824982\/admin\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Twitter<\/strong><\/a>.<\/p>\n<p><strong>BridgeBio Media Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"mailto:contact@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"nofollow noopener\">contact@bridgebiodev.wpengine.com<\/a><br \/>\n(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE)\u00a0\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured [&hellip;]<\/p>\n","protected":false},"author":33,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5935","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE)\u00a0\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T20:02:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-21T14:26:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Koffivi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Koffivi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\",\"name\":\"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2023-06-08T20:02:56+00:00\",\"dateModified\":\"2023-06-21T14:26:45+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/ebdbdf2271900eadf664b81b3ab4afb7\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/ebdbdf2271900eadf664b81b3ab4afb7\",\"name\":\"Koffivi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a71b22b3535365c86ebb40de9dc140ca?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a71b22b3535365c86ebb40de9dc140ca?s=96&d=mm&r=g\",\"caption\":\"Koffivi\"},\"url\":\"https:\/\/bridgebio.com\/author\/kwoglo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio","og_description":"PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE)\u00a0\u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/","og_site_name":"BridgeBio","article_published_time":"2023-06-08T20:02:56+00:00","article_modified_time":"2023-06-21T14:26:45+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Koffivi","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Koffivi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/","name":"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2023-06-08T20:02:56+00:00","dateModified":"2023-06-21T14:26:45+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/ebdbdf2271900eadf664b81b3ab4afb7"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/ebdbdf2271900eadf664b81b3ab4afb7","name":"Koffivi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a71b22b3535365c86ebb40de9dc140ca?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a71b22b3535365c86ebb40de9dc140ca?s=96&d=mm&r=g","caption":"Koffivi"},"url":"https:\/\/bridgebio.com\/author\/kwoglo\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5935"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5935"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5935\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}